D
Protara Therapeutics, Inc. TARA
$3.52 -$0.80-18.52% NASDAQ
Recommendation
Prev Close
$4.32
Volume
72
Avg Vol (90D)
374,779
Market Cap
$158.84M
Dividend & Yield
--
52-Week Range
$1.60 - $10.48
P/E (TTM)
--
EPS (TTM)
-$2.41
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Protara Therapeutics (TARA, $3.52) price exceeded its 50-day Moving Average on April 28, 2025
4/29/2025 - Tickeron - Stocks
Protara Therapeutics (TARA, $3.52) entered Downtrend as Momentum indicator drops below 0 level on Apr 28, 2025
4/29/2025 - Tickeron - Stocks
Protara Therapeutics (TARA, $3.52) price may climb as it broke lower Bollinger Band on Apr 28, 2025
4/29/2025 - Tickeron - Stocks
Protara Therapeutics (TARA, $3.52) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 28, 2025
4/29/2025 - Tickeron - Stocks
Protara Therapeutics Reports Positive Phase 2 Trial Results
4/28/2025 - TipRanks Financial Blog
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the ...
4/26/2025 - GuruFocus
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the ...
4/26/2025 - GuruFocus
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
4/26/2025 - Globe Newswire
Protara Therapeutics (TARA) to Release Quarterly Earnings on Thursday
4/26/2025 - MarketBeat
Protara Therapeutics (TARA, $4.2) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 23, 2025
4/24/2025 - Tickeron - Technical Analysis
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ...
4/23/2025 - GuruFocus
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
4/23/2025 - Globe Newswire
Protara Therapeutics (TARA, $3.94) entered Uptrend as Momentum indicator ascends above 0 level on Apr 22, 2025
4/23/2025 - Tickeron - Stocks
The volume for Protara Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 350% of the 65-Day Volume Moving Average
4/23/2025 - Tickeron - Stocks
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by Analysts
4/18/2025 - MarketBeat
Protara Therapeutics (NASDAQ:TARA) Now Covered by Analysts at Scotiabank
4/18/2025 - MarketBeat
Protara Therapeutics (TARA, $4) price exceeded its 50-day Moving Average on April 16, 2025
4/17/2025 - Tickeron - Technical Analysis
Protara Therapeutics (TARA, $4) entered Downtrend as Momentum indicator drops below 0 level on Apr 16, 2025
4/17/2025 - Tickeron - Technical Analysis
Protara Therapeutics (TARA) Rated Outperform with $12 Target by Scotiabank TARA Stock News
4/16/2025 - GuruFocus
Protara Therapeutics (TARA, $4.17) entered Uptrend as Momentum indicator ascends above 0 level on Apr 15, 2025
4/16/2025 - Tickeron - Stocks
Protara Therapeutics initiated with bullish view at Scotiabank, here's why
4/16/2025 - The Fly
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
4/15/2025 - GuruFocus
Protara Therapeutics (TARA) Names Leonardo Viana Nicacio as New Chief Medical Officer TARA ...
4/15/2025 - GuruFocus
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D. ...
4/15/2025 - GuruFocus
Protara Therapeutics appoints Leonardo Viana Nicacio as chief medical officer
4/15/2025 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$48.82M
EBIT (TTM)
-$49.15M
Net Income (TTM)
-$44.60M
Balance Sheet
Total Assets (Q)
$181.45M
Total Debt (Q)
$4.48M
Total Liabilities (Q)
$14.32M
Book Value Per Share (Q)
$4.77
Cash Flow
Cash from Operations (TTM)
-$35.81M
Cash from Investing (TTM)
$19.16M
Cash from Financing (TTM)
$139.87M
Net Change in Cash (TTM)
$123.21M
Filings
Filing Date
Wednesday, March 5, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
1.45
7-Day Total Return
-12.00%
30-Day Total Return
-18.33%
60-Day Total Return
-21.78%
90-Day Total Return
-41.14%
Year to Date Total Return
-36.92%
1-Year Total Return
20.34%
2-Year Total Return
12.10%
3-Year Total Return
-12.66%
5-Year Total Return
-85.33%
52-week Low
Oct 10, 2024 - $1.60
52-week High
Dec 05, 2024 - $10.48
Valuation
Market Cap
$158.84M - Micro Cap
Enterprise Value
-$6.97M
Price/Sales (TTM)
--
Price/Book (Q)
0.91
Dividends and Shares
Shares Outstanding
26.43M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.protaratx.com
Phone Number
646 844 0337
Address
345 Park Avenue South
New York, NY 10010
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is... more
NASDAQ 04/28/2025 4:00PM Eastern Quotes delayed